Company news
Keymed Biosciences, Inc. (HKEX:2162) news
Keymed Biosciences, Inc. news releases on 6ix. Latest, Aug 20, 2026: Keymed Biosciences Announces 2026 H1 Results and Business Updates
Press releases & updates
Keymed Biosciences Announces 2026 H1 Results and Business Updates
August 20, 2026
Keymed Biosciences Announces 2025 Annual Results and Business Updates
March 26, 2026
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
August 27, 2025
Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine
June 16, 2025
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
June 11, 2025
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
April 25, 2025
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
April 23, 2025
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
April 4, 2025
Keymed Biosciences Announces Annual Results of 2024
March 26, 2025
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
February 10, 2025
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
December 24, 2024
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
March 30, 2023
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration
March 16, 2023
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect
March 7, 2022
Keymed Bio Joins Hang Seng Family of Indexes
February 18, 2022